Tihana Ibrahimpasic1, Ronald Ghossein2, Diane L Carlson3, Iain J Nixon4, Frank L Palmer5, Snehal G Patel6, Robert M Tuttle7, Ashok Shaha8, Jatin P Shah9, Ian Ganly10. 1. Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. tihana_i@yahoo.co.uk. 2. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ghosseir@mskcc.org. 3. Department of Pathology, Cleveland Clinic, Weston, FL, USA. carlsod@ccf.org. 4. Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. iainjnixon@gmail.com. 5. Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. fpalmer16@gsb.columbia.edu. 6. Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. patels@mskcc.org. 7. Department of Endocrinology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. tuttlem@mskcc.org. 8. Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. shahaa@mskcc.org. 9. Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. shahj@mskcc.org. 10. Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ganlyi@mskcc.org.
Abstract
BACKGROUND: Predictive role of undetectable thyroglobulin (Tg) in patients with poorly differentiated thyroid carcinoma (PDTC) is unclear. Our goal was to report on Tg levels following total thyroidectomy and adjuvant RAI in PDTC patients and to correlate Tg levels with recurrence. METHODS: Forty patients with PDTC with no distant metastases at presentation (M0) and managed by total thyroidectomy and adjuvant RAI were identified from a database of 91 PDTC patients. Of these, 31 patients had Tg values recorded and formed the basis of our analysis. A nonstimulated Tg level <1 ng/ml was used as a cutoff point for undetectable Tg levels. Association of patient and tumor characteristics with Tg levels was examined by χ (2) test. Recurrence-free survival (RFS) stratified by postop Tg level was calculated by Kaplan-Meier method and compared by log-rank test. RESULTS: Twenty patients had undetectable Tg (<1 ng/ml) and 11 had detectable Tg (≥1 ng/ml; range 2-129 ng/ml) following surgery. After adjuvant RAI, 24 patients had undetectable Tg (<1 ng/ml) and 7 had detectable Tg (≥1 ng/ml; range 1-57 ng/ml). Patients with undetectable Tg were less likely to have pathologically positive margins compared to those with detectable Tg (33 vs. 72 % respectively; p = 0.03). Patients with undetectable Tg levels had better 5-year regional control and distant control than patients with detectable Tg level (5-year regional recurrence-free survival 96 vs. 69 %; p = 0.03; 5-year distant recurrence-free survival 96 vs. 46 %, p = 0.11). CONCLUSION: Postoperative thyroglobulin levels in subset of patients with PDTC appear to have predictive value for recurrence. Patients with undetectable Tg have a low rate of recurrence.
BACKGROUND: Predictive role of undetectable thyroglobulin (Tg) in patients with poorly differentiated thyroid carcinoma (PDTC) is unclear. Our goal was to report on Tg levels following total thyroidectomy and adjuvant RAI in PDTC patients and to correlate Tg levels with recurrence. METHODS: Forty patients with PDTC with no distant metastases at presentation (M0) and managed by total thyroidectomy and adjuvant RAI were identified from a database of 91 PDTC patients. Of these, 31 patients had Tg values recorded and formed the basis of our analysis. A nonstimulated Tg level <1 ng/ml was used as a cutoff point for undetectable Tg levels. Association of patient and tumor characteristics with Tg levels was examined by χ (2) test. Recurrence-free survival (RFS) stratified by postop Tg level was calculated by Kaplan-Meier method and compared by log-rank test. RESULTS: Twenty patients had undetectable Tg (<1 ng/ml) and 11 had detectable Tg (≥1 ng/ml; range 2-129 ng/ml) following surgery. After adjuvant RAI, 24 patients had undetectable Tg (<1 ng/ml) and 7 had detectable Tg (≥1 ng/ml; range 1-57 ng/ml). Patients with undetectable Tg were less likely to have pathologically positive margins compared to those with detectable Tg (33 vs. 72 % respectively; p = 0.03). Patients with undetectable Tg levels had better 5-year regional control and distant control than patients with detectable Tg level (5-year regional recurrence-free survival 96 vs. 69 %; p = 0.03; 5-year distant recurrence-free survival 96 vs. 46 %, p = 0.11). CONCLUSION: Postoperative thyroglobulin levels in subset of patients with PDTC appear to have predictive value for recurrence. Patients with undetectable Tg have a low rate of recurrence.
Authors: D van Dijk; J T M Plukker; A N A van der Horst-Schrivers; L Jansen; A H Brouwers; A Muller-Kobold; W J Sluiter; T P Links Journal: Clin Endocrinol (Oxf) Date: 2011-01 Impact factor: 3.478
Authors: Enoch M Sanders; Virginia A LiVolsi; James Brierley; Jennifer Shin; Gregory W Randolph Journal: World J Surg Date: 2007-05 Impact factor: 3.352
Authors: David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle Journal: Thyroid Date: 2009-11 Impact factor: 6.568
Authors: Sofia Asioli; Lori A Erickson; Alberto Righi; Long Jin; Marco Volante; Sarah Jenkins; Mauro Papotti; Gianni Bussolati; Ricardo V Lloyd Journal: Mod Pathol Date: 2010-06-18 Impact factor: 7.842
Authors: Tihana Ibrahimpasic; Iain J Nixon; Frank L Palmer; Monica M Whitcher; Robert M Tuttle; Ashok Shaha; Snehal G Patel; Jatin P Shah; Ian Ganly Journal: Surgery Date: 2012-12 Impact factor: 3.982
Authors: Marco Volante; Stefania Landolfi; Luigi Chiusa; Nicola Palestini; Manuela Motta; Alessandra Codegone; Bruno Torchio; Mauro G Papotti Journal: Cancer Date: 2004-03-01 Impact factor: 6.860